AWM
REGN icon

Athena Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Athena Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$639K Buy
1,025
+35
+4% +$23.8K 0.48% 54
2026
Q1 		$765K Buy
990
+401
+68% +$307K 0.63% 45
2025
Q4 		$455K Buy
+589
New +$400K 0.44% 55

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
HCM
Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return

Athena Wealth Management's REGN Position: Q2 2026 in Review

Athena Wealth Management increased its Regeneron Pharmaceuticals (REGN) stake by 3.5% in Q2 2026, buying an estimated $23.8K and bringing the position to 1,025 shares worth $639K. The position accounts for 0.48% of the portfolio, ranked #54.

Athena Wealth Management first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $765K in Q1 2026. 262 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Athena Wealth Management held 1,025 shares of Regeneron Pharmaceuticals worth $639K as of Q2 2026.
  • Athena Wealth Management bought 35 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $23.8K.
  • Regeneron Pharmaceuticals made up 0.48% of Athena Wealth Management's portfolio in Q2 2026, its #54 holding.
  • Athena Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Athena Wealth Management's Regeneron Pharmaceuticals position peaked at $765K in Q1 2026.
  • 262 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Athena Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.